RESEARCH ARTICLE

Changes in antibiotic consumption, AMR and Clostridioides difficile infections in a large tertiary-care center following the implementation of institution-specific guidelines for antimicrobial therapy: A nine-year interrupted time series study

Sebastian G. Schönherr¹, Donald Ranft², Norman Lippmann³,⁴, Christoph Lübbert¹,⁴,⁵*

¹ Division of Infectious Diseases and Tropical Medicine, Department of Medicine II, Leipzig University Hospital, Leipzig, Germany, ² Hospital Pharmacy, Leipzig University Hospital, Leipzig, Germany, ³ Institute for Medical Microbiology and Virology, Leipzig University Hospital, Leipzig, Germany, ⁴ Interdisciplinary Center for Infectious Diseases (ZINF), Leipzig University Hospital, Leipzig, Germany, ⁵ Department of Infectious Diseases/Tropical Medicine, Nephrology and Rheumatology, Hospital St. Georg, Leipzig, Germany

* christoph.luebert@medizin.uni-leipzig.de

Abstract

Background

Institution-specific guidelines (ISGs) within the framework of antimicrobial stewardship programs offer locally tailored decision support taking into account local pathogen and resistance epidemiology as well as national and international guidelines.

Objectives

To assess the impact of ISGs for antimicrobial therapy on antibiotic consumption and subsequent changes in resistance rates and Clostridioides difficile infections (CDIs).

Methods

The study was conducted at the Leipzig University Hospital, a 1,451-bed tertiary-care medical center, and covered the years 2012 to 2020. Since 2014, ISGs were provided to optimize empirical therapies, appropriate diagnostics, and antimicrobial prophylaxis. We used interrupted time series analysis (ITSA) and simple linear regression to analyze changes in antimicrobial consumption, resistance and CDIs.

Results

Over the study period, 1,672,200 defined daily doses (DDD) of antibiotics were dispensed, and 85,645 bacterial isolates as well as 2,576 positive C. difficile cultures were collected. Total antimicrobial consumption decreased by 14% from 2012 to 2020, without clear impact
of the deployment of ISGs. However, implementation of ISGs was associated with significant decreases in the use of substances that were rarely recommended (e.g., fluoroquinolones). Over the whole study period, we observed declining resistance rates to most antibiotic classes of up to 25% in *Enterobacteriales*, staphylococci, and *Pseudomonas aeruginosa*. Switching from ceftriaxone to cefotaxime was associated with reduced resistance to third-generation cephalosporins. The number of CDI cases fell by 65%, from 501 in 2012 to 174 in 2020.

Conclusions

Well-implemented ISGs can have a significant, immediate, and lasting impact on the prescription behavior. ISGs might thereby contribute to reduce resistance rates and CDI incidences in the hospital setting.

Introduction

Background

Antimicrobial resistance (AMR) is considered one of the greatest global health threats [1]. Multidrug-resistant infections are associated with longer hospital stays, higher treatment costs, and increased morbidity and mortality. In Europe alone, over 33,000 annual deaths are attributed to resistant infections [2,3]. Inappropriate and incorrect prescribing is a major driver for resistance and is associated with poorer outcomes [4–6]. In response to the increase in resistance, antimicrobial stewardship (AMS) programs have been widely implemented, aiming to optimize therapies and outcomes. Recent meta-analyses showed that AMS programs were associated with enhanced appropriate use of antimicrobials, reduced incidences of AMR and *Clostridioides difficile* infections (CDIs), shorter hospital stays, and lower therapy costs [7–9].

Institution-specific guidelines (ISGs) are considered an important part of AMS programs, as they offer locally-tailored decision support for empirical therapies while reflecting local pathogen and resistance epidemiology as well as national and other societal recommendations [10,11]. Several studies showed that local guidelines can lead to behavioral changes among physicians, yet few investigated the influence on antimicrobial consumption and resistance [12–16]. The Leipzig University Hospital first introduced ISGs in 2014 as a printed pocket guide; an electronic application was added in 2017 [17,18]. In a previous, survey-based study we found that the ISGs were successfully implemented, regularly used across disciplines and had a perceived influence on physicians’ prescribing behavior [17].

Objectives

In this study we aimed to assess the effects of ISGs on antimicrobial consumption and subsequently the incidence of AMR and CDIs. We hypothesized that, after the implementation of the ISGs, the use of antimicrobial agents that were commonly prescribed prior to the intervention but not often recommended in the ISGs (i.e., ciprofloxacin, sultamicillin, oral cefuroxime, ceftriaxone; Table 1) would be reduced. Subsequently, we expected a decrease in resistance to the respective antibiotics and a decrease in CDI. Conversely, we expected an increased use of antibiotic agents that were not used frequently before the introduction of the ISGs but were recommended frequently, such as cefotaxime, or oral clarithromycin (combination partner for the treatment of community-acquired pneumonia). Furthermore, we aimed to assess whether
there would be secondary effects on the proportion of oral and parenteral antibiotics use, as well as on the proportions of Access, Watch and Reserve antibiotics as defined by the World Health Organization (WHO) AWaRe classification [19].

Methods

Study design

We conducted an observational interrupted time series study with antibiotic consumption, resistance and CDI data to assess the effect of the ISGs. Simple and segmented linear regression models were used to analyze trends and changes thereof. The study is reported in accordance with the STROBE-AMS recommendations of the EQUATOR network [20,21].

Setting

The Leipzig University Hospital (LUH) is a 1,451-bed tertiary-care facility with 29 departments and clinics of all specialties in Leipzig, Germany. Since 2012, several interdisciplinary AMS interventions have been implemented, including regular ward visits by the AMS team, intense training of staff, restriction of selected reserve antibiotics, surveillance of antibiotic consumption and resistance and the implementation of professional ISGs, as described before [17,22–24].

Intervention

The ISGs were developed in cooperation with experts from the represented disciplines and implemented in June 2014. They cover a wide range of infections for many clinical disciplines.
and provide information on empirical treatment, diagnostics and prophylaxis as well as dose adjustments. The current 4th edition of the ISGs (in German) can be accessed online [18].

Participants
All inpatient departments, except pediatrics and psychiatry, were included in the analyses. Psychiatric units were excluded as very few antimicrobials are prescribed there, and pediatric units as they prescribe at small absolute doses. Their inclusion could have led to an underestimation of the antibiotic consumption in the hospital overall. Outpatient departments were excluded since the ISGs are specifically designed for the inpatient setting.

Microbiology
The microbiological analysis focused on isolates from *Klebsiella pneumoniae*, *Escherichia coli*, *Staphylococcus aureus*, *S. epidermidis*, *Enterococcus faecalis*, *E. faecium* and *Pseudomonas aeruginosa* collected 2012 to 2020. All diagnostic samples from the entire hospital with the exception of routine screening material were included in the analysis. In addition, all CDIs confirmed by positive cultures were recorded.

Variables
Antibiotic consumption was measured in monthly defined daily doses (DDD) per 100 bed days (DDD/100BD). We focused on antibiotic agents and antibiotic combinations that met at least one of the following criteria: 1) they were among the 15 most frequently dispensed antimicrobials in the year before the intervention; 2) they were frequently recommended as first-line therapy in the ISGs; 3) they received broad recommendation for at least one very common infection (Table 1). The analysis was done separately for parenteral and oral application. Furthermore, we analyzed relevant commonly used groups (Table 2).

Resistance outcomes were measured annually in percent of total isolates. We used the 2021 EUCAST breakpoints (www.eucast.org) to determine annual resistance rates [25]. The absolute number of positive *C. difficile* routine cultures was used to analyze CDI activity.

Data sources
The hospital pharmacy provided data on antimicrobials dispensed to hospital cost centers (e.g. wards) for the period from 1 January 2012 to 31 December 2020. The data was accessed via the hospital benchmarking software IQVIA Premax (www.iqvia.com). Monthly bed days (BD) of all cost centers were received from the controlling department. Annual MIC data of pathogen isolates and the number of CDIs were provided by the Institute for Medical Microbiology and Virology. German antibiotic resistance data collected in the European Antimicrobial Resistance Network (EARS-Net) was accessed through the ECDC Surveillance Atlas for AMR (www.ecdc.europa.eu/en/antimicrobial-resistance/surveillance-and-disease-data/data-ecdc) [26].

Addressing biases—Exclusion and sub-setting of data
We considered regular ward rounds by the AMS team and interventions by other departments as strong potential confounders. To address this, we ran all analyses again with a subset that did not include wards receiving regular AMS rounds (i.e., intensive care units, pneumology,
Table 2. Results of the interrupted time series analysis of changes in dispensation of antimicrobials in the LUH between 2012 and 2020, associated with the introduction of ISGs and other antibiotic-specific interventions. For fluoroquinolones: Two warning letters ["Rote-Hand-Briefe"] issued by the German Federal Institute for Drugs and Medical Devices (BfArM) in October 2018 and April 2019 warning about serious adverse effects of fluoroquinolones; for trimethoprim/sulfamethoxazole: The introduction of routine real-time PCR for the diagnosis of pneumocystis pneumonia [PCP]). Psychiatric units, pediatric units and outpatient departments were excluded from the analysis.

| Antibiotic agent (application) | Baseline antibiotic consumption in DDD/100BD (95% CI) (β0) | Baseline trend in DDD/100BD per month (95%CI) | Level change one month after the intervention in DDD/100BD (95%CI) | Trend change after the intervention in DDD/100BD per month (95%CI) | Level change one month after the second intervention in DDD/100BD (95%CI) | Trend change after the second intervention in DDD/100BD per month (95%CI) |
|-------------------------------|-------------------------------------------------------------|---------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Total antibiotic consumption  |                                                             |                                             |                                                               |                                                               |                                                               |                                                               |
| Antibiotics                   | 46.9 (44.5 to 49.3) ***                                     | -0.23 (-0.37 to -0.1) **                    | -0.9 (-3.7 to 1.8) **                                         | 0.23 (0.09 to 0.37) **                                         |                                                               |                                                               |
| Antibiotics (P)               | 24.5 (22.9 to 26) ***                                      | -0.07 (-0.16 to 0.01)                      | -1 (-2.7 to 0.8)                                              | 0.16 (0.07 to 0.25) **                                         |                                                               |                                                               |
| Antibiotics (O)               | 22.3 (21.1 to 23.6) ***                                    | -0.16 (-0.23 to -0.09) ***                 | 0.1 (-1.3 to 1.5)                                             | 0.07 (-0.01 to 0.14)                                          |                                                               |                                                               |
| WHO AWaRe Classification      |                                                             |                                             |                                                               |                                                               |                                                               |                                                               |
| Access                        | 16.9 (15.9 to 17.9) ***                                    | -0.1 (-0.16 to -0.04) ***                  | -1.8 (-2.9 to -0.7) **                                        | 0.13 (0.08 to 0.19) **                                         |                                                               |                                                               |
| Watch                         | 30.3 (28.6 to 32) ***                                      | -0.16 (-0.26 to -0.06) **                  | 0.9 (-1 to 2.9)                                              | 0.13 (0.03 to 0.23) **                                         |                                                               |                                                               |
| Reserve                       | 0.9 (0.7 to 1.1) ***                                       | 0.02 (0.01 to 0.03) ***                    | -0.3 (-0.6 to -0.1) **                                        |                                                               | -0.01 (-0.02 to 0)                                           |                                                               |
| Penicillins                   | 9.6 (8.8 to 10.4) ***                                      | -0.01 (-0.06 to 0.04)                      | -0.6 (-1.6 to 0.3)                                           | 0.04 (-0.01 to 0.09)                                          |                                                               |                                                               |
| Penicillin/beta-lactam inhibitor combinations | 7.1 (6.6 to 7.6) ***                                      | -0.03 (-0.05 to 0.00)                      | -1.0 (-1.5 to -0.4) **                                       | 0.03 (0.00 to 0.06)                                           |                                                               |                                                               |
| Ampicillin/sulbactam (P)      | 1.9 (1.7 to 2.2) ***                                       | 0.01 (0 to 0.02)                           | -0.4 (-0.7 to -0.2) **                                       | 0.0 (-0.01 to 0.01)                                           |                                                               |                                                               |
| Sultamicillin (O)             | 2.9 (2.7 to 3.1) ***                                       | -0.04 (-0.05 to -0.02) **                 | -0.4 (-0.7 to -0.2) **                                       | 0.03 (0.01 to 0.04) **                                        |                                                               |                                                               |
| Piperacillin/tazobactam (P)   | 2.2 (2 to 2.5) ***                                         | 0 (-0.01 to 0.02)                           | 0 (-0.3 to 0.3)                                              | 0 (-0.01 to 0.02)                                             |                                                               |                                                               |
| Cephalosporins                | 10.7 (10 to 11.4) ***                                      | -0.07 (-0.11 to -0.03) **                  | -0.1 (-0.9 to 0.7)                                           | 0.08 (0.04 to 0.12) **                                         |                                                               |                                                               |
| 2G Cephalosporins             | 6.6 (6.1 to 7.1) ***                                       | -0.03 (-0.06 to 0)                          | 0.1 (-0.5 to 0.7)                                            | -0.01 (-0.04 to 0.02)                                         |                                                               |                                                               |
| 3G Cephalosporins             | 3.7 (3.2 to 4.1) ***                                       | -0.03 (-0.05 to 0)                          | -0.2 (-0.7 to 0.3)                                           | 0.07 (0.05 to 0.1) **                                         |                                                               |                                                               |
| Cefotaxime (P)                | 0.5 (0.2 to 0.8) ***                                       | 0.01 (-0.01 to 0.02)                        | 0.2 (-0.2 to 0.5)                                            | 0.06 (0.04 to 0.07) **                                        |                                                               |                                                               |
| Ceftriaxone (P)               | 1.9 (1.8 to 2.1) ***                                       | -0.03 (-0.03 to -0.02) **                  | -0.3 (-0.5 to -0.1) **                                       | 0.02 (0.01 to 0.03) **                                        |                                                               |                                                               |
| Cefuroxime (O)                | 4.1 (3.7 to 4.6) ***                                       | -0.02 (-0.05 to 0)                          | 0.1 (-0.4 to 0.5)                                            | -0.01 (-0.03 to 0.02)                                         |                                                               |                                                               |
| Cefuroxime (P)                | 2.4 (2.2 to 2.6) ***                                       | 0 (-0.02 to 0.01)                           | 0.1 (-0.2 to 0.3)                                            | 0 (-0.01 to 0.01)                                             |                                                               |                                                               |
| Fluoroquinolones              | 9.2 (8.6 to 9.8) ***                                       | -0.06 (-0.09 to -0.03) **                  | -0.9 (-1.6 to -0.1) **                                       | 0.04 (0.01 to 0.08) **                                        | -1.7 (-2.5 to -0.9) **                                        | -0.04 (-0.09 to 0)                                           |
| Ciprofloxacin                 | 6.3 (6.1 to 6.9) ***                                       | -0.03 (-0.05 to 0)                          | -1.1 (-1.6 to -0.6) **                                       | 0.01 (-0.01 to 0.04)                                          | -1.1 (-1.7 to -0.5) **                                        | -0.02 (-0.05 to 0.01)                                        |
| Moxifloxacin                  | 1.1 (0.9 to 1.3) ***                                       | -0.01 (-0.02 to 0)                           | 0 (-0.2 to 0.2)                                              | 0 (-0.01 to 0.01)                                             | -0.1 (-0.3 to 0.1)                                            | 0.01 (-0.01 to 0.02)                                         |

(Continued)
gastroenterology, and two surgical wards) and hematologic oncology wards, as these wards have their own antimicrobial therapy recommendations.

A stockout of ampicillin/sulbactam caused a drastic reduction of its use between September 2015 and February 2016; to avoid this as a potential confounder in the analysis we excluded the respective data points in this timeframe [27]. A change in the record keeping system of BD in 2013 caused a large increase in BD (about 40%) without any relevant change of activity in the hospital. To avoid a confounding effect on the outcome variable (DDD/100BD), we adjusted the BD between January 2012 and July 2013 with a correcting factor (1.38) that was determined by comparing the monthly averages of a five-month period that was fully documented in both records (August to December 2013). Old, new, and adjusted monthly BD are plotted in S1 Fig.

Hospital resistance rates are partly determined by external factors such as treatment in other facilities or the spread of resistant strains in the population, and observed changes in resistance rates are therefore not necessarily due to changes in prescribing within the hospital. We therefore also compared our data to selected resistance rates collected in the EARS-Net, to control for broad changes in resistance rates within the German patient population [26]. The documented *S. aureus* resistance rates in the LUH were extremely high in 2014, likely due to a reporting or documentation error, resulting in a strong negative trend in the post-intervention

### Table 2. (Continued)

| Antibiotic agent (application) | Baseline antibiotic consumption in DDD/100BD (95% CI) | Baseline trend in DDD/100BD per month (95%CI) | Level change one month after the intervention in DDD/100BD per month (95%CI) | Trend change after the intervention in DDD/100BD per month (95%CI) | Level change one month after the second intervention in DDD/100BD per month (95%CI) | Trend change after the second intervention in DDD/100BD per month (95%CI) |
|---|---|---|---|---|---|---|
| Levofloxacin | 1.6 (1.3 to 1.8) *** | -0.02 (-0.04 to -0.01) ** | 0.2 (-0.1 to 0.5) | 0.03 (0.01 to 0.05) ** | -0.5 (-0.8 to -0.1) ** | -0.03 (-0.05 to -0.01) * |
| Carapenems | 3.6 (3.3 to 3.9) *** | -0.01 (-0.02 to 0.01) | -0.1 (-0.4 to 0.3) | 0 (-0.02 to 0.02) |
| Meropenem (P) | 1.1 (0.8 to 1.3) *** | 0.01 (-0.01 to 0.02) | 0 (-0.3 to 0.2) | 0 (-0.01 to 0.02) |
| Imipenem (P) | 2.5 (2.3 to 2.7) *** | -0.01 (-0.02 to 0) | 0 (-0.3 to 0.2) | 0 (-0.01 to 0.01) |
| Other antibiotic agents | | | | |
| Trimethoprim/sulfamethoxazole | 1.37 (1.17 to 1.57) *** | -0.01 (-0.02 to 0.01) | -0.43 (-0.73 to -0.12) ** | 0.01 (-0.01 to 0.03) | -0.02 (-0.28 to 0.25) | 0.01 (-0.01 to 0.02) |
| Clarithromycin (O) | 1.8 (1.5 to 2.1) *** | -0.02 (-0.04 to 0) | 0.8 (0.4 to 1.1) **** | 0.01 (-0.01 to 0.03) |
| Clindamycin | 2 (1.6 to 2.3) *** | 0.01 (0 to 0.03) | -0.1 (-0.4 to 0.3) | 0 (-0.02 to 0.02) |
| Vancomycin | 2.3 (2 to 2.6) *** | -0.04 (-0.05 to -0.02) *** | 0.4 (0.1 to 0.7) ** | 0.04 (0.02 to 0.05) **** |
| Metronidazole (P) | 1.3 (1.1 to 1.4) *** | -0.01 (-0.02 to 0) | -0.1 (-0.3 to 0) | 0.01 (0 to 0.02) * |
| Metronidazole (O) | 1.3 (1.1 to 1.4) *** | -0.01 (-0.02 to -0.01) *** | -0.1 (-0.2 to 0) | 0 (0 to 0.01) |

**Abbreviations:** (P) = parenteral, (O) = oral.

* = p < 0.05
** = p < 0.01
*** = p < 0.001

https://doi.org/10.1371/journal.pone.0258690.t002
phase. To avoid misleading results, we did not include 2014 *S. aureus* resistance rates in the analysis.

**Statistical methods**

A segmented linear regression model of interrupted time series was used to analyze the changes in antibiotic consumption, as described before [28–31]. This method allows for the evaluation of immediate changes in level, as well as long-term effects due to trend changes. A time series is a sequence of observations of a certain outcome, which is aggregated for each time point (e.g. DDD/100BD per month). The time series is divided (interrupted) into pre- and post-intervention segments. Least square regression lines are fitted to each segment of the time series and together expressed by the following model [28]:

\[
Y_t = \beta_0 + \beta_1 \cdot \text{time}_t + \beta_2 \cdot \text{intervention}_t + \beta_3 \cdot \text{time after intervention}_t + e_t
\]

In this model, \(Y_t\) is the outcome at time point \(t\), in this case DDD/100BD in each month. Time is a continuous variable counting the number of months of the whole timeframe, intervention is an indicator for the time before (intervention = 0) and after (intervention = 1) the intervention, and time after intervention is a continuous variable counting the time after the intervention. \(\beta_0\) estimates the baseline level at time point zero (y intercept), \(\beta_1\) estimates the baseline trend, \(\beta_2\) estimates the level change between the pre- and the post-intervention period, and \(\beta_3\) estimates the change in trend after the intervention. The sum of \(\beta_1\) and \(\beta_3\) estimates the post-intervention slope. The error \(e_t\) represents the variability not described by the model.

Since the ISGs were implemented in June 2014, July 2014 was chosen as the first time point of the post-intervention period. A second intervention was added in two constellations. First, on 26 June 2016 the microbiology laboratory introduced routine real-time polymerase chain reaction (PCRs) for the diagnosis of pneumocystis pneumonia (PCP). This led to a higher detection rate, and subsequently more prescriptions of trimethoprim/sulfamethoxazole. We considered this a second intervention for trimethoprim/sulfamethoxazole, and so July 2016 was set as the first post-intervention data point. Second, two warning letters ("Rote-Hand-Briefe") had been issued by the German Federal Institute for Drugs and Medical Devices (BfArM) in October 2018 and April 2019, warning of the serious adverse effects of fluoroquinolones [32,33]. These warnings were actively conveyed to hospital physicians by the AMS team and reflected in their recommendations. November 2018 was chosen as the first post-intervention data point.

MIC data was only available in annual aggregates which means that there were not enough data points to run ITSA. We calculated simple linear regressions to determine the trends of resistance rates over the whole study period. To assess national trends of AMR we used annual resistance rates from 2012 to 2019, as data for 2020 was not uploaded at the time of submission [26]. P values of <0.05 were considered statistically significant.

All calculations were carried out using RStudio [34]. The R-code will be shared on request.

**Ethical considerations**

The ethics committee of the Medical Faculty of Leipzig University reviewed and approved the study on January 22, 2019 (registry number 011/19-ek). All data is anonymous.

**Results**

The LUH dispensed a total of 1,672,200 DDD of antibiotics during the study period (excluding pediatric and psychiatric units and outpatient services). The antibiotic groups prescribed most over the study period were penicillins, accounting for 24% of total antibiotic DDD, followed...
by cephalosporins (23%) and fluoroquinolones (15%). The antibiotic agents with the highest overall consumption were cefuroxime (12%), ciprofloxacin (10%), and ampicillin/subactam, including sultamicillin (8%). A total of 4,192,497 adjusted BD were documented. Monthly BD rose slowly over the study period without major changes (S1 Fig). We tested 85,645 isolates of eight pathogens regarding their resistance and collected 2,576 positive *C. difficile* cultures over the study period.

**Antibiotic consumption**

Between 2012 and 2020 the annual antibiotic consumption per 100 BD fell by 14%, from 543 DDD/100BD to 468 DDD/100BD. This reduction mainly occurred prior to the study intervention (Fig 1).

Table 2 shows the results of the ITSA of total antibiotic consumption as well as of different subgroups and antibiotic agents.

Changes in the proportions of AWaRe groups were minimal (Fig 2).

The proportion of Access antibiotics increased by 2%, from 36% in 2012 to 38% in 2020. The intervention was associated with an initial reduction of -1.8 (-2.9 to -0.7, p<0.01) followed by a positive trend with a trend change of +0.13 per month (95%CI 0.08 to 0.19, p<0.001). The introduction of ISGs was associated with an increased use in parenteral antibiotics. With a trend change of +0.09 per month (95%CI 0.04 to 0.14; p<0.001), the proportion of total antibiotic consumption in DDD/100BD increased from 53% in 2012 to 72% in 2020 (Fig 3).

During the study period fluoroquinolone consumption fell by 67%, from 104 DDD/100BD in 2012 to 35 DDD/100BD in 2020. The introduction of ISGs was associated with a large, immediate reduction of ciprofloxacin consumption (-1.1 DDD/100BD; 95%CI -1.6 to -0.6; p<0.001) (Fig 4). A further immediate decrease affecting all fluoroquinolones occurred when

![Fig 1. Total antibiotic consumption in the LUH between 2012 and 2020. Plotted in monthly defined daily doses per 100 bed days (DDD/100BD). Dashed lines represent the start of the antimicrobial stewardship (AMS) program and the implementation of ISGs.](https://doi.org/10.1371/journal.pone.0258690.g001)
Fig 2. Consumption of Access (triangle), Watch (square) and Reserve (circle) antibiotics. As defined by the 2019 WHO AWaRe Classification in the LUH before and after the introduction of ISGs. Squares represent Access antibiotics, triangles represent Watch antibiotics, circles represent Reserve antibiotics, dashed line represents the introduction of ISGs.

https://doi.org/10.1371/journal.pone.0258690.g002

Fig 3. Consumption of oral and parenteral antibiotics in the Leipzig University Hospital between 2012 and 2020. Circles represent parenteral antibiotics, triangles represent oral antibiotics, and dashed line represents the introduction of institution-specific guidelines (ISGs).

https://doi.org/10.1371/journal.pone.0258690.g003
the BfArM issued specific warning letters ("Rote-Hand-Briefe") in 2018 and 2019 (-1.7 DDD/100BD, 95%CI -2.5 to -0.9, p<0.001) [32,33].

For the consumption of cephalosporins, the introduction of ISGs was associated with a positive slope change of +0.08 DDD/100BD (95%CI 0.04 to 0.12, p<0.001). While overall cephalosporin consumption changed only moderately, there were major changes within the antibiotic class (Fig 5): cefuroxime and ceftriaxone prescriptions decreased continuously, with a significant level change for ceftriaxone of -0.3 DDD/100BD (95%CI -0.5 to -0.1, p<0.001) following the ISGs' implementation. Conversely, for cefotaxime, the intervention was associated with a significant positive trend change of +0.06 DDD/100BD per month (95%CI 0.04 to 0.07, p<0.001).

Total penicillin consumption increased by 14% from 112 DDD/100BD in 2012 to 128 DDD/100BD in 2020, without the ISGs having a significant impact, while penicillin and beta-lactamase inhibitor combinations decreased by 14% with a significant level change of -0.96 (95%CI -1.51 to -0.42). The largest reduction (-71%) and a level change of -0.4 DDD/100BD (95%CI -0.7 to -0.1, p<0.01) was observed in sultamicillin. However, decreases were strongest in the pre-intervention phase.

Trimethoprim/sulfamethoxazole prescriptions dropped immediately after the intervention by -0.4 DDD/100BD (95%CI -0.7 to -0.1, p<0.01). Prescriptions increased steadily, though not significantly, when routine Pneumocystis jirovecii PCR was introduced in 2016 (Fig 6).

Vancomycin consumption decreased pre-intervention and converted into a steady state following the intervention which was associated with a level change of +0.4 DDD/100BD (95%CI 0.1 to 0.7, p<0.01) and trend change of +0.04 DDD/100BD per month (95%CI 0.02 to 0.05, p<0.001). Additionally, we observed a level change of prescriptions of oral clarithromycin of +0.8 DDD/100BD (95%CI 0.4 to 1.1, p<0.001).
Fig 5. Consumption of second- and third-generation cephalosporins in the LUH from 2012 to 2020. Before and after the introduction of ISGs. Squares represent cefuroxime, triangles represent ceftriaxone, circles represent cefotaxime, and the dashed line represents the introduction of the ISGs.

https://doi.org/10.1371/journal.pone.0258690.g005

Fig 6. Trimethoprim/sulfamethoxazole consumption in the LUH from 2012 to 2020. Before and after both the introduction of ISGs and introduction of routine real-time polymerase chain reaction (PCR) for the diagnosis of pneumocystis pneumonia (PCP).

https://doi.org/10.1371/journal.pone.0258690.g006
Antibiotic consumption in wards without regular AMS rounds

Furthermore, we ran the ITSA with a subset of the data that excluded wards receiving regular AMS rounds, accounting for 51% of antibiotic consumption documented in the main dataset (S1 Table). Most of the changes observed in the main dataset persisted, e.g. the increase in cefotaxime consumption and a decrease in the prescription rates of fluoroquinolones, ceftriaxone, and sulbactam. Changes in the consumption of clarithromycin and trimethoprim/sulfamethoxazole were not significant.

Changes in resistance

Table 3 shows annual rates of resistance to “focus antibiotics” in isolates of *K. pneumoniae*, *E. coli*, *S. aureus*, and *P. aeruginosa*.

More comprehensive tables including further antibiotic agents as well as *E. faecium*, *E. faecalis*, and *S. epidermidis* isolates can be found in S2 Table, and ITSA results of resistance rates can be found in S3 Table. Rates of resistance to the majority of tested antibiotics, including broad-spectrum penicillins, second and third generation cephalosporins, fluoroquinolones and trimethoprim/sulfamethoxazole decreased significantly in all analyzed pathogens, except in enterococci, where no significant trends were observed. In most cases, resistance rates were already decreasing in the pre-intervention phase and continued to decrease with a more moderate trend after the intervention. Negative trend changes were observed for ciprofloxacin resistance in *E. coli*, *P. aeruginosa* and *S. aureus* as well as cefotaxime resistance in *E. coli*, but these changes were not significant.

Fluoroquinolone-resistance rates among *Enterobacterales*, staphylococci, and *P. aeruginosa* decreased strongly, with relative reductions of ciprofloxacin-resistance ranging between 12% in *P. aeruginosa* (-1.8% per year, 95%CI -2.6 to -0.9, *p*<0.01) to 16% in *S. aureus* (-2.9% per year; 95%CI -5.2 to -0.6, *p*<0.05).

Resistance to second- and third-generation cephalosporins, tested with cefuroxime and cefotaxime, decreased significantly in *Enterobacterales*. For instance, rates of cefuroxime-resistant *K. pneumoniae* decreased by 1.8% per year (95%CI -3.0 to -0.6, *p*<0.05) from 40.5% (366 of 902 cases) in 2012 to 20.1% (200 of 996 cases) in 2020. Similarly, we observed reduced rates of ceftazidime resistance in *P. aeruginosa* (-1.4% per year; 95%CI -2.4 to -0.5; *p*<0.05).

We observed reduced rates of resistance to broad-spectrum penicillins among *Enterobacterales*, as well as staphylococci and pseudomonas. Ampicillin/sulbactam-resistant *E. coli* decreased significantly by 2.4% per year (95%CI -3.2 to -1.5; *p*<0.001) accounting for a relative reduction of almost 25% over the study period. A comparable trend of -1.9 (95%CI -2.9 to -0.9, *p*<0.01) was observed for ampicillin/sulbactam-resistant *K. pneumoniae*. In staphylococci, significantly decreased rates of oxacillin-resistance are indicative of reduced resistance rates to other broad-spectrum penicillins. Interestingly, rates of penicillin G resistance in *S. aureus*, which is expected in penicillinase-producing strains, showed a significant decreasing trend of -2.3% per year (95%CI -3.5 to -1.1; *p*<0.01), accounting for a relative reduction of 15% from 2012 to 2020. Rates of piperacillin/tazobactam resistance decreased significantly, resulting in a relative reduction of almost 20% in *K. pneumoniae* (-2% per year; 95%CI -2.9 to -1.2; *p*<0.01), and 17% in *P. aeruginosa*. (-1.6% per year; 95%CI -2.4 to -0.8; *p*<0.01).

Trimethoprim/sulfamethoxazole resistance showed an overall significant decreasing trend in *Enterobacterales* and staphylococci (e.g. -1.7% per year [95%CI -2.0 to -1.4, *p*<0.001] in *E. coli*, and -2.9% per year [95%CI -4.0 to -1.7, *p*<0.001] in *S. epidermidis*), yet in all of them an increase could be observed in 2020.

Vancomycin-resistance in staphylococci stayed at an extremely low level (0–0.2%).
Table 3. Annual antibiotic resistance rates for selected combinations of pathogens and antibiotics between 2012 and 2020 in the LUH including isolates from all microbiological samples except from routine screenings.

| Pathogen          | Antibiotic agent | 2012 number of resistant isolates (%) | 2013 number of resistant isolates (%) | 2014 number of resistant isolates (%) | 2015 number of resistant isolates (%) | 2016 number of resistant isolates (%) | 2017 number of resistant isolates (%) | 2018 number of resistant isolates (%) | 2019 number of resistant isolates (%) | 2020 number of resistant isolates (%) | Trend: simple linear regression 2012 to 2020 (95% CI)† | Difference of percentile in 2012 vs. 2020 in % |
|--------------------|------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|----------------------------------------|---------------------------------------|
| *Escherichia coli* | Total number of isolates | 3080 (53,6) | 1656 (51,9) | 3379 (43,8) | 3380 (43,7) | 3416 (43,5) | 3262 (43,1) | 3276 (42,6) | 3606 (38,4) | 3539 (28,8) | -2.4 (-3.2 to -1.5) *** | -24.8 |
|                    | Ampicillin/ sulbactam | 1651 (53,6) | 860 (51,9) | 998 (43,8) | 1476 (43,7) | 1484 (43,5) | 1406 (43,1) | 1264 (42,6) | 1381 (38,4) | 1020 (28,8) | -0.9 (-1.3 to -0.5) ** | -5.8 |
|                    | Piperacillin/ tazobactam | 267 (8,7) | 204 (12,3) | 142 (6,2) | 214 (6,3) | 189 (5,5) | 204 (6,3) | 153 (4,7) | 128 (3,6) | 103 (2,9) | -1.0 (-1.5 to -0.5) ** | -6.4 |
|                    | Cefotaxime | 504 (16,4) | 350 (21,1) | 357 (15,7) | 453 (13,4) | 465 (13,6) | 417 (12,8) | 425 (13) | 411 (11,4) | 354 (10) | -1.7 (-2.4 to -1.1) ** | -12 |
|                    | Cefuroxime | 756 (24,5) | 499 (30,1) | 497 (21,8) | 618 (18,3) | 615 (18) | 567 (17,4) | 557 (17) | 543 (15,1) | 442 (12,5) | -1.8 (-2.3 to -1.3) *** | -15.5 |
|                    | Ciprofloxacín | 862 (28) | 426 (25,7) | 622 (27,3) | 795 (23,3) | 797 (23,3) | 753 (23,1) | 647 (19,7) | 556 (15,5) | 441 (12,5) | -2.0 (-2.8 to -1.2) ** | -14 |
|                    | Trimethoprim/ sulfamethoxazole | 1284 (41,7) | 698 (42,1) | 769 (33,8) | 1000 (29,6) | 1028 (30,1) | 930 (28,6) | 836 (25,5) | 942 (26,2) | 979 (27,7) | -0.00 (-0.01 to 0.00) | -0.1 |
|                    | Imipenem | 2 (0,1) | 1 (0,1) | 0 (0) | 1 (0) | 0 (0) | 2 (0,1) | 2 (0,1) | 0 (0) | 1 (0) | 0.00 (0.01 to 0.00) | 0.0 |
| Klebsiella pneumoniae | Total number of isolates | 902 | 626 | 537 | 1006 | 1024 | 782 | 1005 | 1010 | 995 | -1.9 (-2.9 to -0.9) ** | -20.4 |
|                    | Ampicillin/ sulbactam | 388 (43) | 248 (39,6) | 165 (30,7) | 335 (33,3) | 333 (32,6) | 274 (33) | 323 (35,2) | 254 (25,1) | 225 (22,6) | -2.0 (-2.9 to -1.2) ** | -19.4 |
|                    | Piperacillin/ tazobactam | 238 (26,4) | 163 (26) | 87 (16,2) | 176 (17,5) | 169 (16,5) | 165 (21,1) | 129 (12,8) | 128 (12,7) | 70 (7) | -1.0 (-1.5 to -0.4) * | -9.6 |
|                    | Cefotaxime | 219 (24,3) | 128 (20,4) | 87 (16,2) | 153 (15,2) | 157 (15,3) | 129 (16,5) | 165 (16,4) | 135 (13,4) | 146 (14,7) | 1.8 (3.0 to 0.6) * | -20.4 |
|                    | Cefuroxime | 366 (40,5) | 186 (29,7) | 121 (22,5) | 219 (17,5) | 235 (23) | 201 (25,7) | 228 (22,7) | 194 (19,2) | 200 (20,1) | 1.4 (-2.2 to -0.6) ** | -14.3 |
|                    | Ciprofloxacín | 254 (28,2) | 130 (20,8) | 100 (18,6) | 190 (18,9) | 201 (19,6) | 166 (21,2) | 186 (18,5) | 110 (10,9) | 138 (13,9) | -1.2 (-2.0 to -0.4) * | -12.6 |
|                    | Trimethoprim/ sulfamethoxazole | 294 (32,6) | 143 (22,8) | 130 (24,2) | 201 (20) | 231 (22,6) | 211 (23,2) | 164 (16,2) | 199 (20) | 199 (20) | 0.3 (-0.5 to -1.0) * | 3.8 |
| Pseudomonas aeruginosa | Total number of isolates | 826 | 646 | 365 | 973 | 899 | 864 | 788 | 931 | 940 | -1.6 (-2.4 to -0.8) ** | -16.8 |
|                    | Piperacillin/ tazobactam | 212 (25,7) | 137 (21,2) | 53 (14,5) | 124 (12,8) | 115 (12,8) | 137 (15,9) | 118 (15) | 96 (10,3) | 84 (8,9) | -1.4 (-2.4 to -0.5) * | -15 |
|                    | Ceftazidine | 207 (25,1) | 142 (22) | 40 (11) | 119 (12,2) | 137 (15,2) | 139 (16,1) | 112 (14,2) | 89 (9,6) | 95 (10,1) | 0.2 (-1.2 to 0.9) * | -12.1 |
|                    | Ciprofloxacín | 202 (24,5) | 183 (28,3) | 92 (25,2) | 240 (24,7) | 211 (23,5) | 227 (26,3) | 139 (17,6) | 124 (13,3) | 117 (12,4) | 0.5 (-0.8 to 0.2) | -4.7 |
|                    | Meropenem | 65 (7,9) | 54 (8,4) | 16 (5) | 50 (5,1) | 67 (7,4) | 39 (4,5) | 40 (5,1) | 41 (4,4) | 30 (3,2) | 0.0 (-0.8 to 0.2) | 4.7 |
|                    | Imipenem | 140 (16,9) | 136 (21,1) | 76 (20,8) | 257 (26,4) | 239 (26,3) | 208 (24,1) | 146 (18,5) | 135 (14,5) | 129 (13,7) | -0.7 (-1.9 to 0.5) | 3.2 |

(Continued)
Comparison with data from EARS-Net

**S4 Table** shows annual resistance rates of *E. coli, K. pneumoniae, P. aeruginosa,* and *S. aureus* in Germany between 2012 and 2019 [26]. Methicillin-resistant *S. aureus (MRSA)* rates decreased by 1.2% per year (95%CI -1.3 to -1.0, p<0.001), while decreases in other pathogens were very moderate. In the case of third-generation cephalosporin-resistant *E. coli,* rates actually increased (0.38%; 95%CI 0.18 to 0.58, p<0.001). A graphic comparison of resistance rates to fluoroquinolones and third-generation cephalosporins in *Enterobacterales* is given in **Fig 7.**

CDI epidemiology

We observed a large reduction of CDI cases. In 2014, when the ISGs were introduced, culture positive cases had declined by 47% when compared with the previous year (279 vs. 523 cases). Over the whole study period annual CDIs were reduced by 65%, from 501 in 2012 to 174 in 2020 (**Table 4**).

Discussion

In this study, we observed significant reductions in antibiotic use and antibiotic resistance. Most of these occurred in the pre-intervention phase, likely due to other AMS interventions
implemented in 2012. Prescription reductions are expected to be greatest in the first few years after the introduction of AMS interventions and to stabilize after a few years. Since the ISGs were implemented after large initial reductions had already been achieved, the naturally more moderate decreases in antibiotic use and resistance a few years after the start of the AMS program appear as positive trend changes in the ITSA of this intervention. Therefore, we do not consider the positive trend changes in total antibiotic consumption as well as in sultamicillin, ceftriaxone and fluoroquinolones to be a result of the intervention. The same applies for the ITSA of resistance rates.

Overall, it appears that the ISGs did not have a relevant impact on the total quantity of antibiotic prescriptions. However, despite the challenges in interpreting the data, we observed several changes in antibiotic consumption that were clearly associated with the intervention and in line with our predictions, including decreased prescriptions of ciprofloxacin and trimethoprim/sulfamethoxazole, and increased use of cefotaxime and clarithromycin. The ISGs seem to have further contributed to reductions in sultamicillin and ceftriaxone. However, in these cases the result of the ITSA is less reliable given the steep decrease in the pre-intervention

Fig 7. Resistance rates to fluoroquinolones and third-generation cephalosporins in selected Enterobacterales (Klebsiella pneumoniae and Escherichia coli) in the LUH between 2012 and 2020. Plotted annually, compared with the German average reported in the European Antimicrobial Resistance Surveillance Network (EARS-Net) between 2012 and 2020. Blue lines and squares represent rates of fluoroquinolone resistance. Red lines and circles represent third-generation cephalosporin resistance rates. Full lines and shapes represent resistance rates in the LUH, dashed lines and empty shapes represent German resistance rates.

https://doi.org/10.1371/journal.pone.0258690.g007

Table 4. Annual culture-positive Clostridioides difficile cases in the LUH between 2012 and 2020.

| Year | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | Trend: simple linear regression 2012 to 2020 (95%CI) | Difference 2012 to 2020 in % |
|------|------|------|------|------|------|------|------|------|------|------------------------------------------------|-----------------------------|
| Culture-positive Clostridioides difficile cases | 501 | 523 | 279 | 290 | 265 | 207 | 168 | 169 | 174 | -44.6 (61.2 to 28.0) ** | -65% |

https://doi.org/10.1371/journal.pone.0258690.t004
phase. The increased trend and level of vancomycin use can likely be explained with the recommendation for the treatment of CDIs. The ISGs recommend high doses (500 mg QID) of orally-administered vancomycin whereas lower doses (125–250 mg QID) were used before 2014.

Major changes in antibiotic consumption related to the implementation of ISGs, which were found in the analysis of the data from all departments involved, persisted in the analysis of antibiotic use in a subgroup that did not include wards with regular visits by the AMS team (S1 Table). We therefore believe that the ISGs had a relevant independent effect on antibiotic prescriptions. A major unintended effect associated with the ISGs’ implementation was the significant positive-trend change of parenteral applications. This was, in part, likely a result of the successful efforts to reduce the use of sultamicillin, cefuroxime, and ciprofloxacin for empirical antimicrobial treatment, as well as the frequent recommendation of cefotaxime and other parenterally administered antibiotics. A strong potential confounder that may have contributed to this trend is the fact that the German hospital financing system is under increasing pressure to reduce the length of hospital stays. In many cases it is considered necessary that patients are discharged from the hospital as soon as oral administration of antibiotics is possible to avoid financial sanctions. Nevertheless, this finding suggests that the goal of sequential parenteral to oral therapy might not be sufficiently met, which would be in line with responses in a previous survey-based study where several respondents pointed out the need for recommendations for oral antimicrobial therapy [17].

Over the study period, we observed large decreases in antibiotic resistance in almost all key pathogens and for several frequently-used antibiotic groups. Despite many limitations it seems likely that the reductions in resistance are a result of the decreases and changes in antibiotic consumption. It is important to note that the baseline resistance rates in Germany were much lower than that for LUH (as a result a lesser decline would be expected for Germany overall), and that 2019 resistance rates for Germany and LUH were similar [26]. The decreasing trend in oxacillin-resistant S. aureus could be the product of a similar national trend of declining MRSA rates. Yet, this seems not to be the case in other pathogens, particularly for resistance to fluoroquinolones and cephalosporins, for which the national reference resistance rates decreased at most subtly. The quality of the resistance data did not allow for a conclusive analysis of the ISGs’ effect on resistance rates. Given the large reductions in antibiotic use and resistance achieved prior to their introduction, their impact is likely to have been small compared to previous interventions. However, it seems probable that the changes in the use of ciprofloxacin, cephaplosporins, and ampicillin/sulbactam associated with the ISGs’ introduction did contribute to the respective decreases in resistance observed in the post-intervention phase.

One finding of particular interest was that the increased use of third-generation cephalosporins was associated with a significant decrease in resistance to third-generation cephalosporins in E. coli and K. pneumoniae. This is especially noteworthy as the national trend of third-generation cephalosporin-resistant E. coli increased significantly over the study period. We attribute this to the switch from ceftriaxone to cefotaxime within the group of third-generation cephalosporins. One explanation could be that ceftriaxone, as a biliary-excreted antibiotic, might be a stronger driver for resistance in Enterobacterales than cefotaxime [35–37]. The switch from ceftriaxone to cefotaxime might have also contributed to the drastic reduction of CDI (-65%), as proposed in a previous study [38]. Typically, third-generation cephalosporins are considered high-risk antibiotics for the development of CDIs [39]. The fact that CDI declined dramatically despite an overall increase in the use of third-generation cephalosporins suggests that the specific antibiotic agent matters in this case. Additionally, we believe that reduced use of other high-risk antibiotics such as fluoroquinolones likely contributed to
further reductions in CDIs [39,40]. The largest annual reduction (47%) was observed in the year when ISGs were implemented, from 523 cases in 2013 to 279 cases in 2014. It is unlikely that this reduction was mainly due to the ISGs as they were only in place in the second half of 2014, although due to their impact on the high-risk antibiotics mentioned above, they likely contributed to further reductions in subsequent years.

**Limitations**

Since this study is based on routinely documented data without a control group, we can only assess associations and not causations. To analyze antibiotic consumption, we used the pharmacy records of the dispensed antibiotics. Dispensing data holds several limitations. Most importantly, it does not include information on when and whether the dispensed antibiotics were actually used and whether the prescriptions were indicated. Complete surveillance for antibiotic consumption and resistance was only available from the year 2012, when most AMS interventions started. It was therefore not possible to analyze changes due to previous AMS interventions using ITSA.

The fact that antibiotic consumption and resistance rates were already strongly decreasing before the implementation of ISGs makes analyzing their impact with ITSA challenging. We regard other AMS interventions as the strongest confounder. Aside from these AMS interventions, there are many other potential confounders affecting antibiotic consumption, such as new standard operating procedures (SOP) and other department-specific recommendations, as well as stockouts or changed antibiotic prices. Additionally, the current COVID-19 pandemic likely impacted prescriptions in 2020. We addressed such factors wherever possible: by adding a second intervention in the case of fluoroquinolones and trimethoprim/sulfamethoxazole, removing data points of ampicillin/sulbactam affected by a stockout, and analyzing consumption data again after excluding wards receiving AMS rounds.

Resistance rates and CDI numbers were only available as annual aggregates. Hence, a clearly separated microanalysis of resistance rates stratified by those wards receiving regular AMS rounds and those not (especially “heavy users” such as hematologic oncology wards) using aggregated data, is not feasible. The small number of data points and the strong pre-intervention trend make ITSA unreliable for this data. It is therefore not possible to draw clear conclusions regarding the effect of the ISGs on resistance rates and CDIs. Aside of the antimicrobial treatment, there are several confounders that might have impacted resistance rates in our hospital. For example, infection prevention and control interventions may have reduced hospital-acquired infections and thus contributed to lower incidences of CDIs and antibiotic resistance. In addition, given the various factors contributing to the rise and spread of AMR, it is expected that rates of resistance will be largely influenced by external factors, including treatments from other providers. To address this, we compared the resistance trends in our hospital with national trends.

**Conclusions**

This hospital-wide study demonstrated that well-implemented ISGs can have a significant immediate and lasting impact on the choice of agents for antimicrobial therapy. At our institution, ISGs appeared to have contributed to large reductions in resistance rates and incidences of CDI. Hence, we recommend the wider use of ISGs for empirical antibiotic therapy because they are relatively easy to implement, reach all clinicians, and have a significant impact on antibiotic prescribing. We believe that our findings are generalisable to hospitals with a supportive AMS environment and a sufficient awareness of AMR among prescribers.
Supporting information

S1 Fig. Number of monthly bed days (BD) in the Leipzig University Hospital between 2012 and 2020. Triangles represent BD in the old documentation, circles represent bed days in the new documentation, and the solid line represents adjusted BD used for the calculation of DDD/100BD. (TIF)

S1 Table. ITSA of changes in dispensed antimicrobials, excluding wards served by the AMS team–subset. (DOCX)

S2 Table. Annual resistance rates for selected combinations of pathogens and antibiotic agents between 2012 and 2020 in the Leipzig University Hospital–full dataset. (DOCX)

S3 Table. ITSA results of changes in resistance rates in the Leipzig University Hospital between 2012 and 2020, associated with the introduction of ISGs. (DOCX)

S4 Table. Annual German reference antibiotic resistance rates and trends for selected combinations of pathogens and antibiotic agents between 2012 and 2019, collected from the European Antimicrobial Resistance Network (EARS-Net). (DOCX)

Acknowledgments

The authors would like to thank Holger Bogatsch and Meinhard Mende, both scientists at the Department of Medical Computer Science, Statistics and Epidemiology of Leipzig University, for their statistical advice. Furthermore, the authors gratefully acknowledge Nikolaus von Dercks, Head of the Department of Medical Controlling of the Leipzig University Hospital, for providing structural data. We would also like to thank Karin Gröschner and Tim Eckmanns, both scientists from the Robert Koch Institute, Berlin, for their advice on the study design.

Author Contributions

Conceptualization: Sebastian G. Schönherr, Christoph Lübbert.
Data curation: Sebastian G. Schönherr, Donald Ranft, Norman Lippmann, Christoph Lübbert.
Formal analysis: Sebastian G. Schönherr, Donald Ranft, Norman Lippmann, Christoph Lübbert.
Investigation: Sebastian G. Schönherr, Donald Ranft, Christoph Lübbert.
Methodology: Sebastian G. Schönherr, Christoph Lübbert.
Project administration: Sebastian G. Schönherr, Christoph Lübbert.
Resources: Christoph Lübbert.
Software: Sebastian G. Schönherr.
Supervision: Christoph Lübbert.
Validation: Sebastian G. Schönherr, Donald Ranft, Norman Lippmann, Christoph Lübbert.
References

1. World Health Organization (WHO). Ten threats to global health in 2019. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019. Last accessed 8 May 2021.

2. O’Neill J. The Review on Antimicrobial Resistance: Tackling Drug-Resistant Infections Globally: final Report and Recommendations, 2016. https://amr-review.org/. Last accessed 8 May 2021.

3. Cassini A, Högberg LD, Plachouras D, Quattrochi A, Hoilha A, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis 2019; 19: 56–66. https://doi.org/10.1016/S1473-3099(18)30605-4 PMID: 30409683

4. Bell BG, Schellievis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on resistance antibiotic. BMC Infect Dis 2014; 14: 13. https://doi.org/10.1186/s1471-2334-14-13 PMID: 24405683

5. Raman G, Avendano E, Berger S, Menon V. Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: systematic review and meta-analysis. BMC Infect Dis 2015; 15: 395. https://doi.org/10.1186/s12879-015-1123-5 PMID: 26423743

6. Centers for Disease Control and Prevention (CDC). Vital Signs Improving Antibiotic Use Among Hospitalized Patients. MMWR 2014; 63: 194–200. PMID: 24598596

7. Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis 2017; 17: 990–1001. https://doi.org/10.1016/S1473-3099(17)30325-0 PMID: 28629876

8. Davey P, Marwick CA, Scott CL, Charani E, McNeil K, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2017; 2: CD003543. https://doi.org/10.1002/14651858.CD003543.pub4 PMID: 28178770

9. Standiford HC, Chan S, Tripoli M, Weekes E, Forrest GN. Antimicrobial stewardship at a large tertiary care academic medical center: cost analysis before, during, and after a 7-year program. Infect Control Hosp Epidemiol 2012; 33: 338–345. https://doi.org/10.1086/664909 PMID: 22418628

10. Centers for Disease Control and Prevention (CDC). The Core Elements of Hospital Antibiotic Stewardship Programs. https://www.cdc.gov/antibiotic-use/core-elements/hospital.html. Last accessed 8 May 2021.

11. S3-Leitlinie Strategien zur Sicherung rationaler Antibiotika-Anwendung im Krankenhaus. https://www.antibiotic-stewardship.de/fileadmin/media/initiative/Langfassung_der_S3-Leitlinie_Strategien_zur_Sicherung_rationaler_Antibiotika-Anwendung_im_Krankenhaus.pdf. Last accessed 8 May 2021.

12. Chandy SJ, Naik GS, Charles R, Jeyaseelan V, Naumova EN, et al. The impact of policy guidelines on hospital antibiotic use over a decade: a segmented time series analysis. PLOS ONE 2014; 9: e92206. https://doi.org/10.1371/journal.pone.0092206 PMID: 24647339

13. Jenkins TC, Haukoos JS, Young HL, Knepper BC, Shihadeh KC, et al. Patterns of use and perceptions of an institution-specific antibiotic stewardship application among emergency department and urgent care clinicians. Infect Control Hosp Epidemiol 2020; 41: 212–215. https://doi.org/10.1017/ice.2019.331 PMID: 31801647

14. Panesar P, Jones A, Aldous A, Kranzer K, Halpin E, et al. Attitudes and Behaviours to Antimicrobial Prescribing following Introduction of a Smartphone App. PLOS ONE 2016; 11: e0154202. https://doi.org/10.1371/journal.pone.0154202 PMID: 27111775

15. Talpaert MJ, Gopal Rao G, Cooper BS, Wade P. Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. J Antimicrob Chemother 2011; 66: 2168–2174. https://doi.org/10.1093/jac/dkr253 PMID: 21676904

16. Young HL, Shihadeh KC, Skinner AA, Knepper BC, Sankoff J, et al. Implementation of an institution-specific antimicrobial stewardship smartphone application. Infect Control Hosp Epidemiol 2018; 39: 986–988. https://doi.org/10.1017/ice.2018.135 PMID: 29925458

17. Schönherr SG, Wendt S, Ranft D, Schock B, Lübbert C. Assessing the impact of institution-specific guidelines for antimicrobials on doctors’ prescribing behavior at a German tertiary-care center and the
additional benefits of providing a mobile application. PLOS ONE 2020; 15: e0241642. https://doi.org/10.1371/journal.pone.0241642 PMID: 33141858

18. Universitätssklinikum Leipzig. App "Antibiotika—Antinfektiva". https://www.uniklinikum-leipzig.de/Seiten/app-antinfektiva.aspx. Last accessed 8 May 2021.

19. World Health Organization. WHO releases the 2019 AWaRe Classification Antibiotics. https://www.who.int/medicines/news/2019/WHO_releases2019AWaRe_classification_antibiotics/en/. Last accessed 8 May 2021.

20. Elm E von Altman DG, Egger MP, Pocock SJ, Gøtzsche PC. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007; 335: 806–808. https://doi.org/10.1136/bmj.39335.541782.AD PMID: 17947786

21. Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, et al. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open 2016; 6: e010134. https://doi.org/10.1136/bmjopen-2015-010134 PMID: 26895985

22. Schiek S, Ranft D, Truckenbrod C, Dürrbeck A, Chaberny I, et al. [Antibiotics Stewardship Team Recommendations—An Analysis under Routine Conditions in a University Hospital]. Gesundheitswesen 2021 Apr 29. https://doi.org/10.1055/a-1471-5311 Online ahead of print. PMID: 33915578

23. Wendt S, Ranft D, de With K, Kern WV, Salzberger B, Lübbert C. [Antibiotic stewardship (ABS). Part 1: Basics]. Internist 2020; 61: 375–387. https://doi.org/10.1007/s00108-020-00762-8 PMID: 32144476

24. Wendt S, Ranft D, de With K, Kern WV, Salzberger B, Lübbert C. [Antibiotic stewardship (ABS). Part 2: Application]. Internist 2020; 61: 475–486. https://doi.org/10.1007/s00108-020-00763-7 PMID: 32112153

25. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. https://www.eucast.org/clinical_breakpoints/. Last accessed 8 May 2021.

26. European Centre for Disease Prevention and Control (ECDC). Data from the ECDC Surveillance Atlas—Antimicrobial resistance. https://www.ecdc.europa.eu/en/antimicrobial-resistance/surveillance-and-disease-data/data-ecdc. Last accessed 8 May 2021.

27. Redaktion Gelbe Liste. Lieferengpass Ampicillin+Sulbactam-ratiopharm. https://www.gelbe-liste.de/lieferrangpaesse/lieferengpass-ampicillin-sulbactam-ratiopharm. Last accessed 8 May 2021.

28. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002; 27: 299–309. https://doi.org/10.1046/j.1365-2710.2002.00430.x PMID: 12174032

29. Kontopantelis E, Doran T, Springate DA, Buchan I, Reeves D. Regression based quasi-experimental approach when randomisation is not an option: interrupted time series analysis. BMJ 2015; 350: h2750. https://doi.org/10.1136/bmj.h2750 PMID: 26058820

30. Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol 2017; 46: 348–355. https://doi.org/10.1093/ije/dyw098 PMID: 27283160

31. Hernandez-Santiago V, Davey PG, Nathwani D, Marwick CA, Guthrie B. Changes in resistance among coliform bacteraemia associated with a primary care antimicrobial stewardship intervention: A population-based interrupted time series study. PLOS Med 2019; 16: e1002825. https://doi.org/10.1371/journal.pmed.1002825 PMID: 31173597

32. Federal Institute for Drugs and Medical Devices. Rote-Hand-Brief zu Fluorchinolon-Antibiotika: Schwerwiegende und anhaltende, die Lebensqualität beeinträchtigende und möglicherweise irreversible Nebenwirkungen. https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2019/rhb-fluorchinolone.html. Last accessed 8 May 2021.

33. Federal Institute for Drugs and Medical Devices. Rote-Hand-Brief zu Fluorchinolon-Antibiotika: Schwerwiegende und anhaltende, die Lebensqualität beeinträchtigende und möglicherweise irreversible Nebenwirkungen. https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2018/rhb-fluorchinolone.pdf?__blob=publicationFile&v=4. Last accessed 8 May 2021.

34. RStudio Team. RStudio: Integrated Development Environment for R. http://www.rstudio.com/. Last accessed 8 May 2021.

35. Grohs P, Kernéis S, Sabatier B, Lavollay M, Carbonnelle E, et al. Fighting the spread of AmpC-hyper-producing Enterobacteriaceae: beneficial effect of replacing ceftriaxone with cefotaxime. J Antimicrob Chemother 2014; 69: 786–789. https://doi.org/10.1093/jac/dkt403 PMID: 24159154

36. Tan BK, Vivier E, Bouziad KA, Zähr JR, Pommier C, et al. A hospital-wide intervention replacing ceftriaxone with cefotaxime to reduce rate of healthcare-associated infections caused by extended-spectrum
β-lactamase-producing Enterobacteriaceae in the intensive care unit. Intensive Care Med 2018; 44: 672–673. https://doi.org/10.1007/s00134-018-5079-y PMID: 29396655

37. Grégoire M, Berteauf F, Bellouard R, Lebastard Q, Aubert P, et al. A murine model to study the gut bacteria parameters during complex antibiotics like cefotaxime and ceftriaxone treatment. Comput Struct Biotechnol J 2021; 19: 1423–1430. https://doi.org/10.1016/j.csbj.2021.02.019 PMID: 33777338

38. Wendt S, Ranft D, Rodloff AC, Lippmann N, Lübbert C. Switching From Ceftriaxone to Cefotaxime Significantly Contributes to Reducing the Burden of Clostridoides difficile infections. Open Forum Infect Dis 2020; 7: ofaa312. https://doi.org/10.1093/ofid/ofaa312 PMID: 33005693

39. Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014; 69: 881–891. https://doi.org/10.1093/jac/dkt477 PMID: 24324224

40. Brown KA, Khanaf er N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 2013; 57: 2326–2332. https://doi.org/10.1128/AAC.02176-12 PMID: 23478961